Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALDEROL vs CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors (VDR) and suppresses keratinocyte proliferation while inducing differentiation. Betamethasone dipropionate is a potent corticosteroid that binds to glucocorticoid receptors, inhibiting pro-inflammatory mediators and reducing inflammation, pruritus, and vasodilation.
Osteoporosis,Vitamin D deficiency,Renal osteodystrophy,Hypoparathyroidism
FDA: topical treatment of plaque psoriasis in patients 12 years and older,Off-label: scalp psoriasis, nail psoriasis, parapsoriasis
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
Apply to affected areas once daily; maximum weekly dose should not exceed 100 g (calcipotriene 0.005% and betamethasone dipropionate 0.064% as combination ointment or foam).
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Calcipotriene: not applicable due to minimal systemic exposure. Betamethasone dipropionate: terminal half-life of betamethasone after topical application is approximately 5-6 hours.
Hydroxylated in liver to 25-hydroxyvitamin D; further hydroxylated in kidney to active 1,25-dihydroxyvitamin D.
Calcipotriene: hepatic metabolism via CYP24A1 and other enzymes; betamethasone dipropionate: mainly hepatic metabolism via CYP3A4 to various inactive metabolites.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
Calcipotriene: negligible systemic absorption; absorbed fraction undergoes hepatic metabolism and is excreted in feces (approx. 70%) and urine (approx. 20%). Betamethasone dipropionate: absorbed dose metabolized in liver, metabolites excreted primarily in urine (60-70%) and feces (20-30%).
Approximately 99% bound to serum proteins, primarily to vitamin D-binding protein (DBP) and albumin.
Calcipotriene: >90% bound to plasma proteins (albumin). Betamethasone dipropionate: >90% bound to albumin.
Vd is approximately 0.4 L/kg; reflects distribution into total body water with negligible storage in fat.
Calcipotriene: not clinically relevant due to low systemic absorption. Betamethasone dipropionate: Vd of betamethasone is approximately 1.4 L/kg, indicating wide distribution.
Oral bioavailability of calcitriol is approximately 70-90%.
Topical: systemic bioavailability of calcipotriene is <1% of applied dose; betamethasone dipropionate is <10% of applied dose through intact skin, but increases with inflamed skin.
e GFR <30 m L/min/1.73m2: reduce dose by 50% and monitor calcium/phosphate levels; e GFR <15 m L/min/1.73m2: avoid use due to risk of hypercalcemia.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use with caution.
Child-Pugh class B or C: reduce initial dose by 50% and titrate slowly; monitor calcium and albumin levels.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
For hypocalcemia: 0.05-0.1 mcg/kg/day PO, titrated in 0.05 mcg/kg increments every 2-4 weeks; not recommended for IV use in neonates.
Safety and efficacy in pediatric patients (age <12 years) have not been established. For patients 12–17 years, dosing is same as adult; maximum weekly dose not to exceed 60 g per week.
Start at the lowest adult dose (0.25 mcg PO daily); increase cautiously due to reduced renal function; monitor serum calcium and renal function frequently.
No specific dose adjustment required; however, caution due to potential for increased skin atrophy, impaired renal/hepatic function, and concurrent medications. Use minimal effective amount.
None
No FDA boxed warning.
Hypercalcemia,Hypercalciuria,Renal impairment,Monitoring of serum calcium and phosphorus required
May cause hypercalcemia due to calcipotriene absorption, especially when applied to large areas or occluded skin,Risk of hypothalamic-pituitary-adrenal (HPA) axis suppression from betamethasone, particularly with prolonged use, high potency, or large surface area,Local adverse reactions: skin atrophy, striae, telangiectasias, folliculitis, perioral dermatitis, allergic contact dermatitis,Not for use on face, groin, or axillae due to increased systemic absorption and skin atrophy risk,Caution in patients with renal impairment or hepatic impairment due to metabolic and excretory pathways,Do not use with occlusive dressings unless directed,May mask signs of infection and suppress immune response
Hypercalcemia,Vitamin D toxicity,Malabsorption syndrome,Severe renal impairment
Hypersensitivity to calcipotriene, betamethasone dipropionate, or any components,Patients with known hypercalcemia or vitamin D toxicity,Active infections of skin (viral, fungal, bacterial) at treatment site,Concurrent use of other vitamin D analogues topically,Severe renal or hepatic impairment (relative)
Avoid high-calcium foods or supplements unless directed. Vitamin D analogs may alter calcium absorption. No specific food restriction.
No clinically significant food-drug interactions. However, maintain adequate calcium and vitamin D intake as part of a balanced diet, but avoid excessive calcium supplementation due to potential hypercalcemia risk with extensive use.
FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and pulmonary hypertension. Avoid use after 20 weeks gestation.
FDA Pregnancy Category C. Calcipotriene: No adequate human studies; animal studies show no teratogenicity at topical doses. Bethamethasone dipropionate: Corticosteroids can cause cleft palate, intrauterine growth restriction, and adrenal suppression in animal studies; human risk with topical use is low due to minimal systemic absorption. Avoid large areas or prolonged use in pregnancy. First trimester: theoretical risk but limited data. Second/third trimesters: low risk if used sparingly.
Excreted in breast milk; M/P ratio unknown. Potential for adverse vascular effects in infants. Contraindicated in breastfeeding due to risk of ductus arteriosus constriction.
Not known if excreted in human milk. Calcipotriene is likely excreted due to low molecular weight; betamethasone may appear in milk. M/P ratio not available. Use caution; apply smallest amount to smallest area, avoid breast area. Consider benefits vs risks.
No standard dose adjustment. Use lowest effective dose for shortest duration. Contraindicated after 20 weeks gestation; avoid in first trimester if possible due to teratogenic potential.
No formal dose adjustment guidelines. Use minimum effective dose for shortest duration. Avoid occlusion, extensive areas, or prolonged treatment. Monitor for local and systemic adverse effects.
Calderol (calcifediol) is a vitamin D analog used for renal osteodystrophy. Monitor serum calcium and phosphate levels; do not use with severe hypercalcemia or vitamin D toxicity. Dose adjustment needed in dialysis patients.
Avoid use on face, groin, axillae, or in intertriginous areas due to increased risk of corticosteroid side effects. Apply only to affected plaques; limit total weekly dose to ≤100 g or 60 m L to minimize risk of HPA axis suppression. Discontinue if skin atrophy, telangiectasias, or striae develop. Monitor for hypercalcemia in patients with extensive plaque psoriasis due to calcipotriene absorption. For patients with moderate-to-severe plaque psoriasis, consider sequential or rotational therapy to minimize long-term corticosteroid exposure.
Take exactly as prescribed; do not take extra doses.,Avoid calcium supplements and antacids without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, confusion.,Not for use in children.,Store at room temperature away from light and moisture.
Apply a thin layer to psoriatic plaques once daily for up to 4 weeks as directed.,Do not use on the face, armpits, groin, or areas with skin folds.,Wash hands after application unless treating hands.,Avoid contact with eyes and mucous membranes.,Do not use occlusive dressings (e.g., bandages, wraps) over the treated area.,Inform your doctor if you develop severe skin irritation, signs of skin infection, or if psoriasis worsens.,Do not use more than the prescribed amount or for longer than recommended.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALDEROL vs CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE, answered by our medical review team.
CALDEROL is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.. CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is a Vitamin D Analog that works by Calcipotriene is a synthetic vitamin D3 analog that binds to vitamin D receptors (VDR) and suppresses keratinocyte proliferation while inducing differentiation. Betamethasone dipropionate is a potent corticosteroid that binds to glucocorticoid receptors, inhibiting pro-inflammatory mediators and reducing inflammation, pruritus, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALDEROL and CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALDEROL is: Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.. The standard adult dose of CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is: Apply to affected areas once daily; maximum weekly dose should not exceed 100 g (calcipotriene 0.005% and betamethasone dipropionate 0.064% as combination ointment or foam).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALDEROL and CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALDEROL is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramni. CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE is classified as Category C. FDA Pregnancy Category C. Calcipotriene: No adequate human studies; animal studies show no teratogenicity at topical doses. Bethamethasone dipropionate: Corticosteroids can cause c. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.